Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02211222 |
| Title | An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer |
| Recruitment | Approved for marketing |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Eisai Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| La Jolla | California | United States | Details | |||
| Stanford | California | United States | Details | |||
| Torrance | California | United States | Details | |||
| Washington | District of Columbia | United States | Details | |||
| Chicago | Illinois | United States | Details | |||
| Boston | Massachusetts | United States | Details | |||
| Lansing | Michigan | United States | Details | |||
| Lebanon | New Hampshire | United States | Details | |||
| Neptune | New Jersey | United States | Details | |||
| Cleveland | Ohio | United States | Details | |||
| Portland | Oregon | United States | Details | |||
| Philadelphia | Pennsylvania | United States | Details | |||
| Houston | Texas | United States | Details |